INmune Bio Inc. (NASDAQ: INMB) Focusing on New Immunotherapies that Reprogram Immune Systems
INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease INmune Bio’s drug candidates include INKmune, INB03 and XPro1595 INmune Bio Inc. (NASDAQ: INMB) is a diversified, clinical-stage biotechnology company headquartered in La Jolla, California. The company is hoping to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. INmune drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets…